{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants who achieved a best response of either CR or PR per the Lugano Classification.","groups":[{"description":"Participants with Relapsed/Refractory Burkitt Lymphoma received the following treatment during the study: Lymphodepletion chemotherapy regimen of fludarabine 30 mg/m\\^2/day IV and cyclophosphamide 500 mg/m\\^2/day IV for 3 days (Day -5 to Day -3). A single IV infusion of brexucabtagene autoleucel at target dose of 2 × 10\\^6 anti-CD19 CAR T cells/kg on Day 0.","id":"OG000","title":"Substudy C (Relapsed/Refractory Burkitt Lymphoma): Brexucabtagene Autoleucel"}],"populationDescription":"Data cannot be reported for this outcome measure because substudy C was terminated before the central committee could be formed hence central assessment was not performed. There are no plans to analyze these data in the future.","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Substudy C: ORR Determined by Central Assessment Per the Lugano Classification","type":"PRIMARY"}